logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Back
K

Kim Papp

Temerty Faculty of Medicine

106H-index
816Paper Count
4.9WCitation Count
Published Papers 371
Publication Date
logo
Pushing the Boundaries of Topical Therapy in Patients with Atopic Dermatitis: A Review of Baseline Disease Severity and Burden in Clinical Trials
errDermatology and Therapy
IF4.2
err2026-07-14
err0
errOAAI
errMelinda J. Gooderham; H. Chih-ho Hong; Charles Lynde; Yvette Miller-Monthrope; Vimal H. Prajapati; Julien Ringuet; Irina Turchin; Jensen Yeung; Kim A. Papp
errShare
errSave
Pharmacokinetics and safety of candidate biosimilar CT-P55 versus reference secukinumab: a three-arm, randomized, double-blinded, single-dose, multicenter, Phase I study
errExpert Opinion on Investigational Drugs
IF4.1
err2026-02-22
err0
PREAI
errTomoko Hasunuma; Michio Yagi; Noboru Nakamichi; Andrew Blauvelt; Diamant Thaçi; JeeHye Suh; JungBin Cha; IIn Noh; EunKyung Lee; Kim A. Papp
errShare
errSave
Addressing Unmet Needs in Prurigo Nodularis: Expert Canadian Dermatology Perspectives
errDermatologic Therapy
IF3.4
err2026-02-03
err0
errOAAI
errVimal H. Prajapati; H. Chih-Ho Hong; Melinda Gooderham; Kim A. Papp
errShare
errSave
Open-label treatment extension of ruxolitinib cream in vitiligo: findings from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension phase III study
errBRITISH JOURNAL OF DERMATOLOGY
IF9.6
err2026-01-01
err0
errOAAI
errHarris, John E.; Papp, Kim; Ezzedine, Khaled; Sebastian, Michael; Pandya, Amit G.; Seneschal, Julien; Amster, Mark; Shayesteh Alam, Maryam; Forman, Seth B.; Zdybski, Jacek; Nuara, Anthony; Kornacki, Deanna; Wei, Shaoceng; Passeron, Thierry; Rosmarin, David
errShare
errSave
Randomized, double-blind treatment withdrawal or continuation with ruxolitinib cream in vitiligo: findings from the TRuE-V long-term extension phase 3 study
errBritish Journal of Dermatology
IF9.6
err2025-12-26
err0
errOAAI
errJohn E Harris; Kim Papp; Khaled Ezzedine; Michael Sebastian; Amit G Pandya; Julien Seneschal; Mark Amster; Maryam Shayesteh Alam; Seth B Forman; Jacek Zdybski; Anthony Nuara; Deanna Kornacki; Shaoceng Wei; Thierry Passeron; David Rosmarin
errShare
errSave
Results from the 32-week, phase 3 DISCREET study of apremilast in patients with moderate to severe genital psoriasis
errJournal of the European Academy of Dermatology and Venereology
IF8
err2025-12-10
err0
errOAAI
errJoseph F. Merola; Lyn Guenther; Charles Lynde; Kim A. Papp; Lawrence Charles Parish; Paul Yamauchi; Sue Cheng; Hamid Amouzadeh; Cynthia Deignan; Shauna Jardon; Mindy Chen; Andreas Pinter
errShare
errSave
Bimekizumab Impact on Patient-Reported Outcomes in Plaque Psoriasis: 4-Year Results from BE SURE, BE VIVID, BE READY, and BE BRIGHT
errDermatology and Therapy
IF4.2
err2025-12-08
err0
errOAAI
errApril Armstrong; Kim A. Papp; Mark Lebwohl; Laura J. Savage; Keiichi Yamanaka; Diana Elena Vlase; Rhys Warham; Jérémy Lambert; José M. López Pinto; Krista Wixted; Diamant Thaçi
errShare
errSave
361 Lebrikizumab Dosed Every 8 Weeks as Maintenance Provides Long-Lasting Response in Patients with Moderate-to-Severe Atopic Dermatitis
errJournal of Investigative Dermatology
IF5.7
err2025-11-10
err0
PREAI
errJonathan Silverberg; Vivian Laquer; Peter Lio; Kim Papp; Alan Irvine; Andrew Blauvelt; Hany Elmaraghy; Louise DeLuca-Carter; Heidi Crane; Gaia Gallo; Evangeline Pierce; Yuxin Ding; Amy Paller; Lucia Vidal
errShare
errSave
Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis: Pooled PASI and PASI-HD Results from the DERMIS Phase III Trials
errDermatology and Therapy
IF4.2
err2025-10-24
err0
errOAAI
errKim A. Papp; James Q. Del Rosso; Mark G. Lebwohl; Melinda J. Gooderham; Adelaide A. Hebert; H. Chih-ho Hong; Leon H. Kircik; David M. Pariser; Linda Stein Gold; Bruce Strober; Melissa S. Seal; David Krupa; David H. Chu; Patrick Burnett; David R. Berk; Robert C. Higham
errShare
errSave
Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase 3 Clinical Trials of Patients with Vitiligo
errDermatology and Therapy
IF4.2
err2025-10-22
err0
errOAAI
errDavid Rosmarin; Amit G. Pandya; Thierry Passeron; Seth B. Forman; Jacek Zdybski; Mark Amster; Christina Feser; Kim A. Papp; Anthony Nuara; Deanna Kornacki; Shaoceng Wei; Haobo Ren; John E. Harris; Khaled Ezzedine
errShare
errSave
Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension study
errJournal of the European Academy of Dermatology and Venereology
IF8
err2025-10-13
err0
errOAAI
errMatthias Augustin; Marie Tauber; Robert Sidbury; Jonathan I. Silverberg; Kim A. Papp; Diamant Thaçi; Marjolein S. De Bruin-Weller; Adam Reich; Ketty Peris; Kirk Barber; Ryszard Galus; Andrzej Kaszuba; Matthew Zirwas; Walter K. Nahm; Gretel Trullenque; Laura Maintz; Sady Alpizar; Sang Wook Son; Vivian Laquer; Linda Stein Gold; Soo Yeon Cheong; Anna Ryzhkova; Agnes Drahos; Liliana Ulianov; Christophe Piketty
errShare
errSave
Considerations for Treating Generalized Pustular Psoriasis (GPP): A Narrative Review
errDermatology and Therapy
IF4.2
err2025-10-09
err0
errOAAI
errCharles W. Lynde; Vimal H. Prajapati; Melinda J. Gooderham; H. Chih-ho Hong; Mark G. Kirchhof; Perla Lansang; Julien Ringuet; Irina Turchin; Ron Vender; Jensen Yeung; Kim A. Papp
errShare
errSave
Safety and Efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the Phase 2 STRIDE study
errJournal of the American Academy of Dermatology
IF11.8
err2025-10-06
err0
errOAAI
errKim A. Papp; Shahram Jacobs; Howard Sofen; Michael Bukhalo; Elisa Muscianisi; Grace Ma; Gabriel Lau; Michelle Bettinger; Roman G. Rubio; Elena Hitraya; Andrew Blauvelt
errShare
errSave
SPECTREM phase IIIb clinical trial results through week 16: guselkumab efficacy and safety for the treatment of low body surface area, moderate psoriasis with high-impact site involvement
errBRITISH JOURNAL OF DERMATOLOGY
IF9.6
err2025-10-01
err1
errOAAI
errGold, Linda Stein; Gottlieb, Alice B.; Armstrong, April W.; Alkousakis, Theodore; Bissonnette, Robert; Langley, Richard G.; Krueger, James; Papp, Kim; Choi, Olivia; Rowland, Katelyn; Chan, Daphne; Jeyarajah, Jenny; Park-Wyllie, Laura; Gao, Long-Long; Gordon, Kenneth B.; Merola, Joseph F.; Lebwohl, Mark G.; Strober, Bruce
errShare
errSave
Population Pharmacokinetic and Pharmacodynamic Modeling for the Prediction of the Extended Amlitelimab Phase 3 Dosing Regimen in Atopic Dermatitis
errCPT: Pharmacometrics & Systems Pharmacology
IF0
err2025-10-01
err0
errOAAI
errGilles Tiraboschi; Kim Papp; Thomas Bieber; Stephan Weidinger; Lisa Beck; Chih-Hung Lee; John T. O'Malley; Karl Yen; Charlotte Bernigaud; David Fabre; Fabrice Hurbin
errShare
errSave
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Randomized Clinical Trials
errRheumatology and Therapy
IF2.9
err2025-09-30
err0
errOAAI
errAndrew Östör; Filip Van den Bosch; Kim Papp; Mauro Keiserman; Ricardo Blanco; Angela Crowley; Douglas White; Ana Biljan; Tshepiso Madihlaba; Kyle Carter; Fang Liu; Ahmed M. Soliman; Doug Ashley; Michael Chen; Lila Glotfelty; Alan Kivitz
errShare
errSave
Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials
errlancet
IF0
err2025-09-18
err0
PREAI
errLinda Stein Gold; April W Armstrong; Robert Bissonnette; Nina Magnolo; Ronald B Vender; Michael Sebastian; Maria Laura Galimberti; Athanasios Tsianakas; Marcelo Arnone; Paul Wallace; Margrit Simon; Josep Riera-Monroig; Sascha Gerdes; Jill Waibel; Alvaro Gonzalez-Cantero; Beate Schwarz; Yayoi Tada; Michael Cecchini; Benjamin Ehst; Leon Kircik; Lea Kephart; Ofelia Reyes-Servin; Bassey Effiom Edem; Jennifer H Campbell; Yaung-Kaung Shen; Kellen Cresswell; Shu Li; Cynthia M C DeKlotz; Fabio Nunes; Kim A Papp
errShare
errSave
Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks
errAmerican Journal of Clinical Dermatology
IF8.8
err2025-09-03
err0
errOAAI
errAlan D. Irvine; Vimal H. Prajapati; Emma Guttman-Yassky; Eric L. Simpson; Kim A. Papp; Andrew Blauvelt; Chia-Yu Chu; H. Chih-ho Hong; Linda F. Stein Gold; Marjolein de Bruin-Weller; Thomas Bieber; Kenji Kabashima; David Rosmarin; Cristina Sancho; Brian M. Calimlim; Ayman Grada; Yang Yang; Xiaoqiang Wu; Gweneth Levy; Eliza M. Raymundo; Henrique D. Teixeira; Jonathan I. Silverberg
errShare
errSave
Amlitelimab, an anti-OX40 ligand antibody, for atopic dermatitis: a plain language summary of STREAM-AD clinical study
errImmunotherapy
IF2.9
err2025-09-01
err0
errOAAI
errStephan Weidinger; Andrew Blauvelt; Kim A. Papp; Adam Reich; Chih-Hung Lee; Margitta Worm; Charles Lynde; Yoko Kataoka; Peter Foley; Xiaodan Wei; Wanling Wong; Anne-Catherine Solente; Christine Weber; Samuel Adelman; Sonya Davey; Fabrice Hurbin; Natalie Rynkiewicz; Karl Yen; John T. O’Malley; Charlotte Bernigaud
errShare
errSave
Comparative molecular analysis of IL-17A and IL-23 pathway inhibition in moderate-to-severe psoriasis: 4-week results from IXORA-R
errJournal of Investigative Dermatology
IF5.7
err2025-08-15
err0
PREAI
errSandra Garcet; Lam C. Tsoi; Hong Hur; Andrew Blauvelt; Kim A. Papp; Bruce Konicek; Zhe Sun; Richard E. Higgs; Ernst R. Dow; David C. Gemperline; Gaia Gallo; Hany Elmaraghy; Brian J. Nickoloff; Venkatesh Krishnan; James G. Krueger; Johann E. Gudjonsson
errShare
errSave

Research Directions

No research directions
Co-authors
Cooperation Journals
D
David Cella
H-index: 184 · Papers: 1.9K
I
Iain B. McInnes
H-index: 144 · Papers: 1.3K
D
Dafna D. Gladman
H-index: 143 · Papers: 1.6K
J
James G. Krueger
H-index: 143 · Papers: 745
C
C.E.M. Griffiths
H-index: 131 · Papers: 1.3K
View more